1.866.771.8946

LinkedIn Google+ Twitter Facebook

Pioneering Cancer Detection

Carisome, a new blood-based technology, may revolutionize cancer detection.

Cancer detection and screening have become topics of hot debate in recent years:

  • In 2009, the United States Preventive Services Task Force concluded that women between 40 and 50 did not show enough benefit to warrant annual or biannual mammograms, reversing previous guidance.1
  • In 2011, the same panel concluded that the widely used prostate-specific antigen (PSA) test does not save men’s lives and should no longer be used as a cancer screening tool.2

While many disagree with these new guidelines, the controversies point to urgent unmet clinical needs for better cancer detection technologies.

Carisome Circulating Microvesicle Technology

Currently in development, Carisome has the potential to aid doctors in detecting early stage cancers.

Carisome uses a proprietary method to capture and profile sub-cellular particles in the blood called circulating microvesicles or cMVs. These cMVs are released into the blood from tissue. By detecting specific markers on cMVs, Carisome is able to identify cMVs that indicate disease states.

The first Carisome test in development will be used to aid in the detection of prostate cancer.

Learn more about Carisome

Learn more about circulating microvesicles

1. “Panel Urges Mammograms at 50, Not 40,” New York Times, 11/16/2009.

2. “U.S. Panel Says No to Prostate Screening for Healthy Men,” New York Times, 10/6/11.

Carisome


Caris Life Sciences Molecular Oncology Services

Representing a revolution in blood-based diagnostics, prognostics and therapeutic guidance.

learn more

Caris Presents


Caris Life Sciences Molecular Oncology Services

Caris' scientific experts contribute to the advancement of science at various symposia and conferences worldwide.

learn more